Mechanistic illustration on lipid-metabolism disorders induced by triclosan exposure from the viewpoint of m6A-RNA epigenetic modification

Chen, Shuya; Wang, Xuedong; Yan, Jin; Wang, Zejun; Qian, Qiuhui; Wang, Huili

doi:10.1016/j.scitotenv.2023.165953

Cited by 7 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have found that MNNG, as a typical environmental chemical carcinogen, is strongly associated with the occurrence of GC, and that prolonged exposure to MNNG increases the expression of METTL3 and EMT markers 155 . Similarly, triclosan (TCS), a typical anthropogenic pollutant, can reduce m6A modification by targeted upregulation of ‘erasers’ and downregulation of YTHDF1, leading to disruption of lipid metabolism 156 . Recent research advances in the field of epigenomics (epigenetic genomics) have suggested a link between reprogramming of elements involved in the epigenetic transcription machinery and the development of cancer.…”

Section: Discussionmentioning

confidence: 99%

“…155 Similarly, triclosan (TCS), a typical anthropogenic pollutant, can reduce m6A modification by targeted upregulation of ‘erasers’ and downregulation of YTHDF1, leading to disruption of lipid metabolism. 156 Recent research advances in the field of epigenomics (epigenetic genomics) have suggested a link between reprogramming of elements involved in the epigenetic transcription machinery and the development of cancer. The dynamic expression patterns of these regulators make it difficult to determine the specific consequences of aberrant accumulation of modifications in RNA metabolism.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy

Chen,

Liu,

Zhang

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

RNA methylation is widespread in nature. Abnormal expression of proteins associated with RNA methylation is strongly associated with a number of human diseases including cancer. Increasing evidence suggests that targeting RNA methylation holds promise for cancer treatment. This review specifically describes several common RNA modifications, such as the relatively well‐studied N6‐methyladenosine, as well as 5‐methylcytosine and pseudouridine (Ψ). The regulatory factors involved in these modifications and their roles in RNA are also comprehensively discussed. We summarise the diverse regulatory functions of these modifications across different types of RNAs. Furthermore, we elucidate the structural characteristics of these modifications along with the development of specific inhibitors targeting them. Additionally, recent advancements in small molecule inhibitors targeting RNA modifications are presented to underscore their immense potential and clinical significance in enhancing therapeutic efficacy against cancer.Key Points In this paper, several important types of RNA modifications and their related regulatory factors are systematically summarised. Several regulatory factors related to RNA modification types were associated with cancer progression, and their relationships with cancer cell migration, invasion, drug resistance and immune environment were summarised. In this paper, the inhibitors targeting different regulators that have been proposed in recent studies are summarised in detail, which is of great significance for the development of RNA modification regulators and cancer treatment in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%